Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

GATIFLOXACIN

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (S01A, S01AE) — coverage varies; not interchangeable

  • Moxifloxacin (Vigamox): not a benefit
  • Framycetin (Soframycin): general benefit
  • Gentamicin (Garamycin): general benefit
  • Bacitracin zinc + polymyxin b (Polysporin): general benefit
  • Tobramycin (Tobrex): general benefit

Apo-Gatifloxacin (with preservative) · DIN 02327260 · 0.3% w/v · Oph Sol

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Gatifloxacin (with preservative) · DIN 02327260 Manufacturer: Apotex Inc.; listing date 2019-12-20 Health Canada: Marketed since 2019-11-15 · brand APO-GATIFLOXACIN · ATC S01AE06 GATIFLOXACIN · form Solution · route Ophthalmic · ingredients GATIFLOXACIN (GATIFLOXACIN HEMIHYDRATE) 0.3 % · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81256 · Verify on the e-Formulary ↗ (DIN 02327260)

Source record
DIN 02327260: Apo-Gatifloxacin (with preservative) Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 520404049; group id 578; item number 1533; lccId None; manufacturer id APX Source form: Oph Sol; strength: 0.3% w/v Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.0320; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02327260 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81256
Interchangeable products
Jamp Gatifloxacin · DIN 02533235 · not recorded Zymar (with preservative) · DIN 02257270 · not recorded
Shortage status: active shortage (reported 2025-08-12, estimated to end 2026-09-04, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02327260
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Gatifloxacin · DIN 02533235 · 0.3% w/v · Oph Sol

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Gatifloxacin · DIN 02533235 Manufacturer: Jamp Pharma Corporation; listing date 2024-09-27 Health Canada: Marketed since 2024-12-05 · brand JAMP GATIFLOXACIN · ATC S01AE06 GATIFLOXACIN · form Solution · route Ophthalmic · ingredients GATIFLOXACIN 0.3 %/W/V · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102224 · Verify on the e-Formulary ↗ (DIN 02533235)

Source record
DIN 02533235: Jamp Gatifloxacin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 520404049; group id 578; item number 1533; lccId None; manufacturer id JPC Source form: Oph Sol; strength: 0.3% w/v Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.0320; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02533235 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102224
Interchangeable products
Apo-Gatifloxacin (with preservative) · DIN 02327260 · not recorded Zymar (with preservative) · DIN 02257270 · not recorded
Shortage status: active shortage (reported 2026-01-23, estimated to end 2026-11-15, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02533235
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zymar (with preservative) · DIN 02257270 · 0.3% w/v · Oph Sol

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Zymar (with preservative) · DIN 02257270 Manufacturer: Allergan Inc.; listing date 2019-12-20 Health Canada: Marketed since 2023-12-06 · brand ZYMAR · ATC S01AE06 GATIFLOXACIN · form Solution · route Ophthalmic · ingredients GATIFLOXACIN 0.3 %/W/V · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Zymar (with preservative): Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74247 · Verify on the e-Formulary ↗ (DIN 02257270)

Source record
DIN 02257270: Zymar (with preservative) Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 520404049; group id 578; item number 1533; lccId None; manufacturer id ALL Source form: Oph Sol; strength: 0.3% w/v Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02257270 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74247
Interchangeable products
Apo-Gatifloxacin (with preservative) · DIN 02327260 · not recorded Jamp Gatifloxacin · DIN 02533235 · not recorded
Shortage status: resolved shortage (ended 2026-05-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02257270
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (52:04:04 Antibiotics) and how they are covered

Matched class: 52:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FRAMYCETIN SULFATE, FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE, GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE, GENTAMICIN SULFATE, POLYMYXIN B SULFATE & BACITRACIN (ZINC), POLYMYXIN B SULFATE & GRAMICIDIN, TOBRAMYCIN, TOBRAMYCIN & DEXAMETHASONE 52:04:04 Antibiotics

MOXIFLOXACIN HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5% · Oph Sol-3mL Pk (Preservative-Free)

FRAMYCETIN SULFATE

· 2 products · General benefit · strengths: 0.5% · Oph Oint-5g Pk, Oph Sol

GENTAMICIN SULFATE

· 1 products · General benefit · strengths: 0.3% · Oph Oint-3.5g Pk

POLYMYXIN B SULFATE & BACITRACIN (ZINC)

· 1 products · General benefit · strengths: 10000U & 500U/g · Oph Oint 3.5g Pk

TOBRAMYCIN

· 3 products · General benefit · strengths: 0.3% · Oph Oint, Oph Sol

FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE

· 1 products · General benefit · strengths: 5mg & 50mcg & 0.5mg/mL · Oph/Ot Sol

GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE

· 1 products · General benefit · strengths: 3mg & 1mg/mL · Oph/Ot Drops

POLYMYXIN B SULFATE & GRAMICIDIN

· 1 products · General benefit · strengths: 10000U & 0.025mg/mL · Oph/Ot Sol

TOBRAMYCIN & DEXAMETHASONE

· 2 products · General benefit · strengths: 0.3% & 0.1% · Oph Oint, Oph Susp

CIPROFLOXACIN AND DEXAMETHASONE

· 3 products · Limited Use, codes 509 · strengths: 0.3% w/v & 0.1% w/v · Otic Susp-7.5mL Pk (With Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:04:04
Full class listing Related classes: 52:04:12 Other Anti-Infectives, 52:08:92 Anti-Inflammatory Agents, Miscellaneous Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: patients 1 year of age and older with bacterial conjunctivitis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. MOXIFLOXACIN HYDROCHLORIDE · Listed, not a benefit (1), General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (8) INDICATIONS AND CLINICAL USE VIGAMOX® (moxifloxacin ophthalmic solution) is indicated for the treatment of patients 1 year of age and older with bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic, Gram-Positive Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Streptococcus pneumoniae Streptococcus viridans group Aerobic, Gram-Negative Acinetobacter species Haemophilus influenza To reduce the development of the drug-resistant bacteria and maintain the effectiveness of VIGAMOX and other antibacterial drugs, VIGAMOX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. PM: https://pdf.hres.ca/dpd_pm/00042774.PDF; date December 1, 2017; DIN 02252260; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS ZYMAR® (gatifloxacin) is indicated for the treatment of patients 1 year of age and older with bacterial conjunctivitis caused by susceptible strains of the following bacteria: Aerobic Gram-positive bacteria: • Staphylococcus aureus • Staphylococcus epidermidis • Streptococcus pneumoniae Aerobic Gram-negative bacteria: • Haemophilus influenzae To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYMAR and other antibacterial drugs, ZYMAR should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Pediatrics Pediatrics (≥ 1 year and ≤ 12 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of ZYMAR in pediatric patients 1 year of age and older has been established; therefore, Health Canada has authorized an indication for pediatric use. See 7.1.3 Pediatrics. 1.2 Geriatrics Geriatrics (> 65 years of age): No overall differences in safety or effectiveness have been observed between elderly and younger patients. https://pdf.hres.ca/dpd_pm/00067074.PDF PM date: AUG 30, 2004 Source product: ZYMAR; DIN 02257270; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Gatifloxacin (with preservative) · DIN 02327260 Shortage status: active shortage (reported 2025-08-12, estimated to end 2026-09-04, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02327260

Check this DIN again

Jamp Gatifloxacin · DIN 02533235 Shortage status: active shortage (reported 2026-01-23, estimated to end 2026-11-15, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02533235

Check this DIN again

Other review policies

For Apo-Gatifloxacin (with preservative), Jamp Gatifloxacin, Zymar (with preservative): no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026